Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance.
Iannelli F, Zotti AI, Roca MS, Grumetti L, Lombardi R, Moccia T, Vitagliano C, Milone MR, Ciardiello C, Bruzzese F, Leone A, Cavalcanti E, De Cecio R, Iachetta G, Valiante S, Ionna F, Caponigro F, Di Gennaro E, Budillon A. Iannelli F, et al. Among authors: zotti ai. Front Cell Dev Biol. 2020 Aug 17;8:732. doi: 10.3389/fcell.2020.00732. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 33015030 Free PMC article.
Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.
Terranova-Barberio M, Roca MS, Zotti AI, Leone A, Bruzzese F, Vitagliano C, Scogliamiglio G, Russo D, D'Angelo G, Franco R, Budillon A, Di Gennaro E. Terranova-Barberio M, et al. Among authors: zotti ai. Oncotarget. 2016 Feb 16;7(7):7715-31. doi: 10.18632/oncotarget.6802. Oncotarget. 2016. PMID: 26735339 Free PMC article.
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F, Di Gennaro E, Ionna F, Longo F, Aversa C, Pavone E, Maglione MG, Di Marzo M, Muto P, Cavalcanti E, Petrillo A, Sandomenico F, Maiolino P, D'Aniello R, Botti G, De Cecio R, Losito NS, Scala S, Trotta A, Zotti AI, Bruzzese F, Daponte A, Calogero E, Montano M, Pontone M, De Feo G, Perri F, Budillon A. Caponigro F, et al. Among authors: zotti ai. BMC Cancer. 2016 Nov 25;16(1):918. doi: 10.1186/s12885-016-2957-y. BMC Cancer. 2016. PMID: 27884140 Free PMC article. Clinical Trial.
Synthesis of Arylpiperazine Derivatives as Protease Activated Receptor 1 Antagonists and Their Evaluation as Antiproliferative Agents.
Zotti AI, Di Gennaro E, Corvino A, Frecentese F, Magli E, Perissutti E, Cirino G, Roviezzo F, Terranova-Barberio M, Iannelli F, Caliendo G, Santagada V, Fiorino F, Budillon A, Severino B. Zotti AI, et al. Anticancer Agents Med Chem. 2017;17(7):973-981. doi: 10.2174/1871520616666160926120904. Anticancer Agents Med Chem. 2017. PMID: 27671294
[Post therapeutic PNX empyema].
Fiorentino G, Cardone M, Zotti A. Fiorentino G, et al. Infez Med. 1996;4(4):238-40. Infez Med. 1996. PMID: 12858031 Italian.